EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Projected Cost Savings With Optimal Medication Adherence in Patients With Cardiovascular Disease Requiring Lipid‐Lowering Therapy: A Multinational Economic Evaluation Study

Jeong-Yeon Cho iD, Fernando A Wilson iD, Usa Chaikledkaew iD, Yingyao Chen iD, Arintaya Phrommintikul iD, Miguel Angel Diaz-Aguilera, Zhenyue Chen, Kyoo Kim iD, Nathorn Chaiyakunapruk iD

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.124.037792 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Jeong-Yeon Cho und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy College of Pharmacy, University of Utah Salt Lake City UT USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Markov Chains, Quality-Adjusted Life Years, Cost Savings. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poor adherence to chronic cardiovascular treatments can impede targeted clinical outcomes. This study estimates the potential benefits of improving adherence among patients with cardiovascular disease requiring secondary prevention in Mexico, Thailand, and China. Methods and Results We performed Markov model simulation for patients with cardiovascular disease in 3 countries from health care and societal perspectives over a lifetime horizon. Two scenarios were compared: (1) optimal adherence based on a meta‐analysis of 51 randomized controlled trials and (2) status quo. The association between adherence and cardiovascular disease outcomes derives from a dose–response meta‐analysis of 4 051 338 patients. Outcomes include the accumulated number of cardiovascular events and associated costs in 2022 US dollars, life years, and quality‐adjusted life years. Optimal adherence could prevent 42 (95% credible interval [CrI], 29–56) cardiovascular events in Mexico, 34 (95% CrI, 24–50) in Thailand, and 63 (95% CrI, 43–89) in China per 1000 patients over a lifetime. Incremental effectiveness per patient was 0.60 (95% CrI, 0.47–0.74) life‐years in Mexico, 0.68 (95% CrI, 0.37–0.94) quality‐adjusted life years in Thailand, and 0.93 (95% CrI, 0.44–1.27) quality‐adjusted life years in China. Cost savings from societal perspective amounted to $412 (95% CrI, $211–$723), $316 (95% CrI, $187–$541), and $700 (95% CrI, $355–$1144) per patient for Mexico, Thailand, and China, respectively. Findings remained cost saving in deterministic and probabilistic sensitivity analyses.

Conclusions

Achieving optimal adherence in patients with cardiovascular disease requiring lipid‐lowering therapy saves costs and improves health outcomes in Mexico, Thailand, and China. These findings support national health care systems implementing strategies to improve adherence in these countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesMarkov ChainsQuality-Adjusted Life YearsCost SavingsCost-Benefit AnalysisDrug MonitoringHumansThailandChinaMexicoMiddle AgedMaleFemaleAgedModels, EconomicHypolipidemic AgentsTreatment OutcomeDrug CostsSecondary Prevention

Stichwörter der Autor:innen

cardiovascular diseaseeconomic evaluationhealth economicslipid‐lowering therapymedication adherence

Substanzen

Hypolipidemic Agents

Autor:innen und Institutionen

  • Department of Pharmacotherapy College of Pharmacy, University of Utah Salt Lake City UT USA.
  • Matheson Center for Health Care Studies University of Utah Salt Lake City UT USA.
  • Social Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy Mahidol University Bangkok Thailand.
  • School of Public Health Fudan University Shanghai China.
  • Division of Cardiology, Department of Internal Medicine, Faculty of Medicine Chiang Mai University Chiang Mai Thailand.
  • Secretaria de Salud/CENAPRECE Mexico City Mexico.

ORCID-Profile: Jeong-Yeon Cho, Fernando A Wilson, Usa Chaikledkaew, Yingyao Chen, Arintaya Phrommintikul, Kyoo Kim, Nathorn Chaiyakunapruk

Zitieren

APA

Cho, J. Y., Wilson, F. A., Chaikledkaew, U., Chen, Y., Phrommintikul, A., Diaz-Aguilera, M. A., Chen, Z., Kim, K., & Chaiyakunapruk, N. (2024). Projected Cost Savings With Optimal Medication Adherence in Patients With Cardiovascular Disease Requiring Lipid‐Lowering Therapy: A Multinational Economic Evaluation Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.037792

Vancouver

Cho JY, Wilson FA, Chaikledkaew U, Chen Y, Phrommintikul A, Diaz-Aguilera MA, et al. Projected Cost Savings With Optimal Medication Adherence in Patients With Cardiovascular Disease Requiring Lipid‐Lowering Therapy: A Multinational Economic Evaluation Study. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.037792

BibTeX
@article{Cho2024,
  author = {Cho, Jeong-Yeon and Wilson, Fernando A and Chaikledkaew, Usa and Chen, Yingyao and Phrommintikul, Arintaya and Diaz-Aguilera, Miguel Angel and Chen, Zhenyue and Kim, Kyoo and Chaiyakunapruk, Nathorn},
  title = {Projected Cost Savings With Optimal Medication Adherence in Patients With Cardiovascular Disease Requiring Lipid‐Lowering Therapy: A Multinational Economic Evaluation Study},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.124.037792}
}
Kostenlos starten →